Early Feasibility Study of the CardiAQ Transcatheter Mitral Valve Implantation (TMVI) System Transfemoral and Transapical Delivery Systems), For the Treatment of Moderate to Severe Mitral Regurgitation Study
Sponsor: |
Edwards Lifesciences |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAQ5112 |
U.S. Govt. ID: |
NCT02515539 |
Contact: |
Martin Leon: 212-342-3617 / ml2398@cumc.columbia.edu |
The goal of this study is to assess the safety and function of this new device to insert an artificial mitral valve. This study is for patients who are a high risk candidate for standard openheart surgery to treat their mitral regurgitation. The standard medical treatments generally available to patients with mitral regurgitation who do not undergo surgery may improve some of the symptoms, but will not fix the condition or cure their mitral regurgitation. Patients involved will be evaluated on how they are doing with the device and if the device is working as it supposed to.
This study is closed
Investigator
Martin Leon, MD
Do you have mitral regurgitation? |
Yes |
No |